-

05:04:19 PM

Latest APLS Stock Market News

APLS - Apellis Pharmaceuticals Inc

02/22/21 8:00 AM

Nasdaq : APLS

conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in March: Raymond James 42nd Annual

RHEA-AI

neutral

02/18/21 4:05 PM

Nasdaq : APLS

earnings

Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2020

RHEA-AI

neutral

02/05/21 4:05 PM

Nasdaq : APLS

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to fourteen new employees with grant date of February 1,

RHEA-AI

very positive

01/26/21 5:00 PM

Nasdaq : APLS

Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”)

RHEA-AI

neutral

01/21/21 7:00 AM

Nasdaq : APLS

conferences

Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment

RHEA-AI

neutral

01/07/21 6:55 AM

Nasdaq : APLS

Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500%

RHEA-AI

neutral

01/05/21 7:00 AM

Nasdaq : APLS

conferences

Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

RHEA-AI

neutral

12/10/20 6:00 AM

Nasdaq : APLS

clinical trial

Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH

Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48 , which is equal to the 2.7 g/dL increase seen at Week 16 with pegcetacoplan-treated patients S ustained improvements in transfusion avoidance, reticulocyte count

RHEA-AI

neutral

12/07/20 10:00 AM

Nasdaq : APLS

Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH

Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7 % of patients treated with pegcetacoplan compared to 5.1% of eculizumab -treated patients achieved a good , major, or complete hematologic response based on

RHEA-AI

positive

12/04/20 4:05 PM

Nasdaq : APLS

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to two new employees with grant date of December 1, 2020, as

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 Next

APLS Data

industryPharmaceutical Preparation Manufacturing
websiteapellis.com
ceo
security nameApellis Pharmaceuticals Inc
issue typecs
sectorManufacturing
sic code2834
employees
tagsDistribution Services,Medical Distributors,Health Technology,Pharmaceuticals: Major,Manufacturing,Pharmaceutical Preparation Manufacturing
address100 Fifth Avenue
address2
stateMassachusetts
cityWaltham
zip02451
countryUnited States
phone16179775700

APLS Description:

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.